Posters

      Selection of biomarkers of exposure for a population study of U.S. adult smokers to cigarette smoke

      Kinser, R. D.; Carchman, R. A.; Leyden, D. E.; Sanders, E. B.; Stabbert, R.; Tricker, A. R.; von Holt, K.; R-Walk, R-A. Walk.
      Conference date
      Jun 8, 2001
      Conference name
      IXTH International Congress of Toxicology (ICT)
      Link to more information
      Link to more information
      Topic
      Summary

      In our paradigm for the evaluation of harm reduction by new cigarette designs, measurements of exposure to both the gas/vapor phase and particulate phase ('tar') of mainstream cigarette smoke are required. We have identified biomarkers based on known mainstream cigarette smoke chemistry and the need to investigate toxicologically relevant smoke constituents. Selected biomarkers of gas/vapor phase smoke exposure are CO in exhaled breath, blood COHb, and acetonitrile in both exhaled breath and blood. Relevant biomarkers of particulate phase smoke exposure are hemoglobin adducts of the aromatic amines 3- and 4-aminobiphenyl, 24 h excretion of two urinary metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and the sum total of six urinary metabolites of nicotine. A justification for the smoke constituents chosen for study, the criteria used to select the above biomarkers of cigarette smoke exposure, and the pilot study planned to evaluate these choices will be presented. 

      Related Publications

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      Smoking and apolipoprotein levels: A meta-analysis of published data

      Clinical

      Effect of switching from cigarette smoking to the use of the tobacco heating system on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study

      Clinical

      Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate Modified Risk Tobacco Product: A randomized trial

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.